The human antimelanoma antibody V86 was cloned from a single-chain Fv molecule (scFv) 
patient immunized with genetically-modified autologous tumor cells. Previous ELISA tests for binding of the V86 fusion phage to a panel of human metastatic melanoma and carcinoma cell lines and primary cultures of normal melanocytes, endothelial, and fibroblast cells showed that measurable binding occurred only to the melanoma cells. In this communication, the strict specificity of V86 for melanoma cells was confirmed by immunohistochemical staining tests with cultured cells and frozen tissue sections. The V86 fusion phage stained melanoma cell lines but did not stain carcinoma cell lines or cultured normal cells; V86 also stained specifically the melanoma cells in sections of metastatic tissue but did not stain any of the cells in sections from normal skin, lung, and kidney or from metastatic colon and ovarian carcinomas and a benign nevus. An unexpected finding is that V86 contains a complete VH domain but only a short segment of a VL domain, which terminates before the CDR1 region. This VL deletion resulted from the occurrence in the VL cDNA of a restriction site, which was cleaved during construction of the scFv library. Thus V86 is essentially a VH antibody. The effect of adding a VL domain to V86 was examined by constructing scFv fusion phage libraries in which V86 was coupled to VA or VK domains from the original scFv library of the melanoma patient and then panning the libraries against melanoma cells to enrich for the highest affinity antibody clones. None of the V86-VA clones showed significant binding to melanoma cells in ELISA tests; although binding occurred with most of the V86-V,K clones, it was generally weaker than the binding of V86.
These results indicate that most of the VL domains in the original scFv library reduce or eliminate the affinity of V86 for melanoma cells. Accordingly, VH libraries could provide access to anti-tumor antibodies that might not be detected in scFv or Fab libraries because of the incompatibility of most randomly paired VH and VL domains.
In an earlier communication (1) we described a general procedure for cloning anti-tumor antibodies from single-chain Fv molecule (scFv) fusion phage libraries derived from peripheral blood lymphocytes of cancer patients who were vaccinated with genetically modified tumor cells. The antibodies are selected by panning the libraries against the tumor cells. The vast repertoire of human antibodies that could be screened in this way constitutes a potentially rich source of anti-tumor antibodies for immunodiagnosis and immunotherapy and for isolating tumor-specific antigens. This procedure was used to clone from two vaccinated melanoma patients antibodies that react specifically with human melanoma cells or melanocytic-lineage cells in ELISA tests (1) and fixed in 0.24% glutaraldehyde at room temperature for 10 min. The fixed sections were used for immunohistochemistry as described for cultured cells.
DNA Sequencing. A single bacterium colony carrying a phage clone was inoculated into 50 ml of 2 x TY tet broth and grown overnight; the bacteria were removed by centrifugation, and the supernatant medium was filtered through a 0.45-,m membrane. The phage in the medium were precipitated by adding 0.2 volume of a 20% polyethylene glycol 8000/2.5 M NaCl stock solution, and the phage were pelleted and resuspended in PBS. The precipitation procedure was repeated once, and the phage pellet was resuspended in 100 ,ul of water. The phage DNA was extracted twice with phenol/chloroform and once with chloroform, and the DNA was precipitated with ethanol/NaAc and resuspended in 50 ,ul of water. The primer for sequencing the VL domain was TGATTTTCTGTAT-GAGG, which hybridizes 90 bases away from the 5'-end of gene-3 of the phage; the primer for sequencing the VH domain was ACCCGACCCACCACCGCCCGA, which hybridizes to the linker of the scFv molecule. A full description of this sequencing procedure has been published (2).
Construction of V86-VA and V86-V, Libraries. The cDNA encoding the VH domain of V86 was synthesized by PCR from the V86 fusion phage clone (1) . The sequence of the 5'-primer was ATTATTATTCGCAATTCCTTTAG, which hybridizes to the third gene of the phage, and the sequence of the 3'-primer was GCCACCCGACCCACCACCGCCCGAGC-CACCTGARGAGACGGTGACCRKKGTYCC, which includes part of the JH and linker sequences (1) . The cDNAs encoding the VK and VA domains were synthesized from peripheral blood lymphocytes of melanoma patient DM414 as described previously (1) . To construct the V86-VA and V86-VK scFv cDNAs, the complementary linker sequences were hybridized, and the cDNAs were synthesized by PCR as described (2) . The procedure involved adding 10 ng of V86 cDNA and 10 ng of VK or VA cDNAs to 100 ,ul of PCR reagents and cycling seven times at 94°C for 1 min, 60°C for 1 min, and 72°C for 2 min; 10 pM of a mixture of VH back primers and 10 pM of JK or JA forward primers (1) were then added, and the PCR synthesis was continued for 25 cycles. The PCR products were precipitated with ethanol and purified by electrophoresis in 1% LMT-agarose gel and extraction with 03-agarose. To construct the fusion phage libraries; the scFv cDNAs and the replicative form of the fUSE5 DNA (2) were digested with SfiI and ligated in 100 ,ul of reaction mixture containing 1.5 10 times with PBS at room temperature. The attached phage were eluted from the cells in 2 ml of E-buffer for 10 min at room temperature and immediately neutralized with 0.375 ml N-buffer (2). The eluted phage were mixed with 15 ml of Escherichia coli K91 Kan cells, and after 30 min at room temperature, the cells were plated on 2 x TY tet agar (2) . The colonies were collected in 50 ml of 2 x TY tet medium and incubated for 1 hr. The bacteria were pelleted, and the supernatant medium was filtered through a 0.45-,um membrane. For each subsequent panning step, the amplified phage from the previous panning step were precipitated in 4% PEG/0.5 M NaCl and resuspended in water, and about 1011 transforming units of the phage were used for panning against melanoma cells A2058 as described for the first panning step.
Preparation of Fusion Phage Clones. The phage were mixed with E. coli K91 Kan cells at low phage to cell ratios, and the cells were plated on 2 x TY tet agar (2) . Individual colonies were inoculated into 2 ml of 2 x TY tet medium and grown overnight. The cells were pelleted, and the medium containing the cloned phage was used for the initial ELISA assays. For the assays reported in Figs. 1 and 2 , the medium was filtered through a 0.45-,um membrane and precipitated in 4% PEG/0.5 M NaCl twice. The phage titer in each cloned stock was determined as described (2) and adjusted to contain 1010 phage transforming units per ml.
ELISA Assays. The cells were grown in 96-well microtiter plates until almost confluent, washed with PBS, and fixed with 0.24% glutaraldehyde for 30 min at room temperature. The fixed cells were washed with PBS, and the wells were filled with DMEM/10% FCS and kept for 1 hr at room temperature. The wells were emptied, and 100 ,ul of a stock of cloned phage diluted 1:1 with DMEM/10% FCS was added to each well.
After 2 hr at room temperature, the wells were washed rapidly 10 times with PBS, and the amount of bound phage was assayed using a peroxidase-conjugated anti-M13 polyclonal antibody and O-phenylenediamine as the peroxidase substrate (Pharmacia Detection Module). All assays were done in triplicate.
Restriction Analysis of V86-VA and V86-VK cDNAs. The cDNA insert in a phage clone was synthesized by PCR using the 5'-primer ATTATTATTCGCAATTCCTTTAG and the 3'-primer GAATTTTCTGTATGAGGTTTTGCT, which hybridize to phage sequences flanking the insert. The purified cDNA products were digested separately with Sau3AI and Hinfl, and the digests were analyzed by electrophoresis in 2% agarose gel.
Relative Binding Affinities of the Fusion Phage Antibodies to Melanoma Cells. The melanoma cell line A2058 was harvested from culture flasks in PBS/10 mM EDTA, and the cells were pelleted and resuspended in DMEM/10% FCS. A phage stock was serially diluted in DMEM, and each diluted sample was added to 5 x 105 melanoma cells. After incubation with gentle rotation at room temperature for 2 hr, the cells were washed 3 times by centrifugation at 3000 rpm in a microfuge for 3 min and resuspended in PBS. The phage remaining bound to the cells after the third centrifugation were eluted with 400 ,ul of E-buffer for 10 min at room temperature and were neutralized immediately with 75 ,lI N-buffer (2) . The total phage and eluted phage titers were determined by infecting a suspension of E. coli K91 Kan cells from a frozen stock for 1 hr at room temperature and plating the cells on 2
x TY tet agar (2). The relative affinities of the fusion phage antibodies were calculated as described for monoclonal antibodies (3) . (Fig. 2) GGGGSGGGGSGGGGS SYELTQEPRGGGTQLTVLGGAAGA The amino acid sequence was derived from the nucleotide sequence of the cDNA insert in the V86 fusion phage. The completeVH domain is followed by the linker and the truncated VL domain. The V86-VA and V86-VK clones are random isolates from the two fusion phage libraries, each expressing the V86-VH domain linked either to VA or VK domains from the original scFv library. The melanoma cell line for the ELISA tests was A2058. The ELISA absorbance scales are as follows: + + +, >0.8; + +, 0.8-0.5; +, 0.5-0.1; -, <0.1. The absorbance for V86 without a VL domain is 1.0.
RESULTS
determined by restriction mapping the cDNAs in the fusion phage, were tested by ELISA for binding to the melanoma cell line A2058 ( Table 2) . None of the V86-VA clones showed detectable binding, indicating that VA domains are incompatible partners for V86; most of the V86-V,K clones showed significant binding, but it was generally weaker than the binding of V86. Thus most of the VL partners for V86 reduce or eliminate its capacity to bind to melanoma cells. The V86-VA and V86-VK libraries were then panned twice against melanoma cells to enrich for any higher affinity antibodies that might be present, and clones of the panned phage containing different VA or VK. domains were tested by ELISA for binding to the melanoma line A2058. As before, binding occurred with the V86-V, clones and not with the V86-VA clones. The relative binding affinities for A2058 cells of 15 panned V86-V" clones were determined, using a Scatchard plot assay (3). The results showed that the affinity of V86 was the highest (Fig. 3) , suggesting that V86 functions more effectively as a VH than as a scFv anti-melanoma antibody. The panned V86-VK clones were also tested by ELISA for specific binding to melanoma cells, using a panel of cells consisting of A2058, four carcinoma lines and primary cultures of melanocyte, endothelial, and fibroblast cells. All of the V86-VK clones bound only to the melanoma cells (data not shown), indicating that addition of a VK domain to V86 affects only its affinity but not its specificity for melanoma cells. A natural repertoire of functional heavy chain antibodies has been reported in the camel (10) . The antibodies are composed of two identical disulfide-linked heavy chains each containing a VH, CH2, and CH3 domain. The camel also has a minor population of antibodies with the expected composition of two complete heavy chains and two complete light chains. This remarkable discovery raises intriguing questions concerning the evolutionary and functional significance of heavy chain antibodies. It also provides additional evidence that a functional antibody need not contain a VL domain.
DISCUSSION
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